BridgeBio Pharma (BBIO) Company Overview

We have just released a list of 10 Unstoppable Stocks to Invest in for 2025. In this article, we will examine how BridgeBio Pharma, Inc. (NASDAQ:BBIO) compares to other top stocks to buy in 2025. According to the latest earnings report from FactSet on January 24, 2025, the earnings season for Q4 2024 is underway.

Attruby's recent approval makes BBIO a direct rival to PFE's Vyndaqel in treating ATTR-CM. With a 42% decrease in heart failure risk and 90% TTR stabilization, Attruby may offer better results than Vyndaqel in certain situations. Additionally, BBIO is expected to receive $500 million in milestone payments for Attruby's approval, along with another $105 million from approvals in the EU and Japan.

Neil Kumar, the CEO of BridgeBio, appears on CNBC's 'Power Lunch' to talk about the company's newest drug advancements, how these drugs stack up against rivals, and other related topics.

We have just released a list of 10 companies that led the rise on Monday. In this article, we will examine how BridgeBio Pharma, Inc. (NASDAQ:BBIO) compares to these other firms that experienced significant gains. Most of these ten companies are in the healthcare sector and started Monday's trading with impressive increases due to various business updates and earnings reports.

BridgeBio Pharma (BBIO) experienced a significant rise in its stock price during the last trading session, with trading volume exceeding the usual amount. However, the recent changes in earnings estimates might not lead to additional price growth in the short term.

There has been impressive early demand for Attruby, with 430 scripts written by 248 different healthcare professionals since it received FDA approval. This interest spans both academic and community centers, covering a wide range of patient types.

PALO ALTO, Calif., Dec. 13, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) is a biopharmaceutical company that focuses on genetic diseases. Today, they announced that the Committee for Medicinal Products for Human Use (CHMP) has given a positive recommendation for marketing authorization in the European Union (EU) for acoramidis, a treatment for wild-type or variant transthyretin amyloidosis in adults with cardiomyopathy (ATTR-CM). In the Phase 3 study ATTRibute-CM, acoramidis demonstrated significant improvements in cardiovascular outcomes.

SANTA CRUZ, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Unnatural Products, Inc. (UNP), a biotech company working on oral macrocyclic peptides for hard-to-target diseases, has announced that BridgeBio Pharma, Inc. (Nasdaq: BBIO) has chosen to license some of the macrocyclic peptide candidates found through UNP's advanced AI-driven chemistry platform.

BridgeBio has received FDA approval for Attruby (acoramidis) to treat patients with ATTR-CM. The approval comes with a clear label that contains all important clinical information. Additionally, this approval activates a $500 million milestone payment to BridgeBio from a royalty-backed agreement made earlier this year, alleviating some regulatory and funding concerns for the company.